Somapacitan
Somatropin and Somatropin Agonists
Sold as Sogroya
- Drug class
- Somatropin and Somatropin Agonists
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 7
Overview
Somapacitan is an active pharmaceutical ingredient in the Somatropin and Somatropin Agonists group (H01AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | May 15, 2026 |
| EU European Union | EMA | 1 | December 4, 2025 |
| CA Canada | Health Canada | 3 | May 27, 2026 |
GBUnited Kingdom· MHRA
3 products
Uses
Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
How to take
EUEuropean Union· EMA
1 product
Uses
Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
How to take
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (1)
Drug interactions
Known interactions involving Somapacitan. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 347. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB046680434 · revised July 25, 2025
- [2]European Medicines Agency · EMEA/H/C/005030 · revised December 4, 2025
- [3]Health Canada (DPD) · 02539934 · revised May 27, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.